High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

The Duration of Antigenic Stimulation Determines the Fate of Naive and Effector T Cells

1998 • 890 citations

Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.

1995 • 552 citations

T Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis

1994 • 530 citations

Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

1996 • 520 citations

Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma

1997 • 405 citations

Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.

1991 • 402 citations

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

1996 • 290 citations

Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL.

1996 • 222 citations

Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.

1996 • 208 citations

Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).

1996 • 182 citations

Development of Cancer Immunotherapies Based on Identification of the Genes Encoding Cancer Regression Antigens

1996 • 132 citations

Immunobiology of Human Melanoma Antigens MART-1 and gp100 and their Use for Immuno-Gene Therapy

1997 • 104 citations

Enhanced Immune Priming with Spatial Distribution of Paracrine Cytokine Vaccines

1996 • 67 citations

Antitumor Immunization with a Minimal Peptide Epitope (G9–209–2M) Leads to a Functionally Heterogeneous CTL Response

1999 • 67 citations

Murine tumor antigens: is it worth the search?

1996 • 51 citations